Klotho gene therapy is expected to reverse organ degeneration, with the stock price soaring 787% in a single day

According to Zhitong Finance APP, Klotho Neurosciences (KLTO.US) announced early research results showing that its proprietary gene therapy may fully reverse age-related organ degeneration. The company's stock price surged 787% in the U.S. stock market, and this extreme increase was maintained until the market close, triggering a "biotech frenzy trading" mode in the U.S. stock market, attracting global funds to flow into the stock. In recent years, the anti-aging gene and longevity economy narrative have frequently sparked speculation in the global secondary market, with investor sentiment being highly sensitive to any "longevity" signals.

Preclinical trials from Klotho Neurosciences indicate that enhancing Klotho gene expression can slow down the process of organ degeneration with age. Driven by this positive news, the stock price soared by as much as 787% by the market close, with trading volume exceeding 1.1 billion shares, far surpassing normal levels.

Meanwhile, Synaptogenix (SNPX.US) entered the cryptocurrency field by investing $10 million to purchase the AI-focused "tao" cryptocurrency token, and as of Monday's close, its stock price rose over 44%. These moves highlight how innovation is reshaping market dynamics.

The single-day surge in Klotho Neurosciences' stock price demonstrates that cutting-edge biotech research can quickly ignite investment enthusiasm and amplify trading volume. With Synaptogenix announcing its entry into the cryptocurrency and AI sectors, the market is closely watching technological changes and may recalibrate investment focus. Investors looking to capitalize on cutting-edge technology trends need to weigh the investment risks and opportunities in a rapidly innovating environment.

The progress of Klotho Neurosciences also reflects a broader biotech trend—exploring the use of gene therapy to combat degenerative diseases. Such technological leaps will not only profoundly impact the pace of global medical development but also reshape market and regulatory landscapes. As innovation accelerates, the intersection of cutting-edge biotech and investment strategies is becoming a major focus for global market participants.

Data shows that Klotho Neurosciences is a U.S. micro biotech company focused on "anti-aging" and gene therapy for neurodegenerative diseases. The reason for the stock price surge of over 780% yesterday is primarily due to the company releasing the latest animal experiment data on α-Klotho gene therapy, indicating its potential to delay or even reverse multi-organ aging, which instantly ignited market enthusiasm for the "small-cap anti-aging concept." Additionally, the influx of global funds and the very small circulating share volume, coupled with a surge in turnover, amplified price volatility.

Klotho stated that in various animal models, the delivery of the s-Klotho gene via AAV significantly improved heart, liver, kidney, and brain function indicators, with signs of extended lifespan. The company's latest announcement emphasized that it has obtained exclusive global patent licensing and plans to apply for an FDA preclinical meeting (Pre-IND).

Klotho Neurosciences' core technology lies in developing in vivo gene therapy for delaying degenerative changes in the central nervous system and multiple organs due to aging, using a patented secretory α-Klotho (s-KL) gene delivery vector for single or low-frequency administration The product pipeline mainly includes: AAV-Klotho gene therapy (preclinical) targeting Alzheimer's disease, Parkinson's disease, and ALS, as well as exogenous recombinant s-KL protein supplementation therapy (preclinical).

Klotho Neurosciences has attracted global speculative funds and quantitative trading into the stock due to the release of eye-catching early results of longevity/anti-aging gene therapy, combined with its ultra-small market capitalization characteristics. However, for investors in the biotechnology theme, the risk of investing in Klotho lies in the fact that current data is limited to animal experiments, far from human trials and commercialization, with a high degree of uncertainty regarding success rates, regulatory pathways, and funding requirements; in addition, the company's financial fundamentals are very weak, with limited cash on hand and no revenue, and it may require multiple rounds of financing in the future, leading to dilution